<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1812246447
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Ondex
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ONDANSETRON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.8
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        90.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAUDI PHARMACEUTICAL INDUSTRIES" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAUDI PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1023]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAUDI PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ondex contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.</p><p>Ondex is used for:</p><ul><li>preventing nausea and vomiting caused by chemotherapy (in adults and children) or radiotherapy for cancer (adults only)</li><li>preventing nausea and vomiting after surgery.</li></ul><p>Ask your doctor, nurse or pharmacist if you would like any further explanation about these uses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Ondex if:</strong></p><ul><li>you are taking apomorphine (used to treat Parkinson&rsquo;s disease)</li><li>you are allergic (hypersensitive) to ondansetron or any of the other ingredients in Ondex (listed in section 6).</li></ul><p>If you are not sure, talk to your doctor, nurse or pharmacist before taking Ondex.</p><p><strong>Warnings and precautions</strong><br />Check with your doctor, nurse or pharmacist before taking Ondex if:</p><ul><li>you have ever had heart problems (e.g., congestive heart failure which causes shortness of breath and swollen ankles)</li><li>you have an uneven heart beat (arrhythmias)</li><li>you are allergic to medicines similar to ondansetron, such as granisetron or palonosetron</li><li>you have liver problems</li><li>you have a blockage in your gut</li><li>you have problems with the levels of salts in your blood, such as potassium, sodium and magnesium.</li></ul><p>If you are not sure if any of the above apply to you, talk to your doctor, nurse or pharmacist before taking Ondex.</p><p><strong>Other medicines and Ondex</strong><br />Please tell your doctor, nurse or pharmacist if you are taking, or have recently taken, or might take any other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because Ondex can affect the way some medicines work. Also some other medicines can affect the way Ondex works.</p><p>In particular, tell your doctor, nurse or pharmacist if you are taking any of the following medicines:</p><ul><li>carbamazepine or phenytoin used to treat epilepsy</li><li>rifampicin used to treat infections such as tuberculosis (TB)</li><li>antibiotics such as erythromycin or ketoconazole</li><li>anti-arrhythmic medicines used to treat an uneven heart beat</li><li>beta-blocker medicines used to treat certain heart or eye problems, anxiety or prevent migraines</li><li>tramadol, a pain killer</li><li>medicines that affect the heart (such as haloperidol or methadone)</li><li>cancer medicines (especially anthracyclines and trastuzumab)</li><li>SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram</li><li>SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety including venlafaxine, duloxetine</li></ul><p>If you are not sure if any of the above applies to you, talk to your doctor, nurse or pharmacist before having Ondex.</p><p><strong>Tell your doctor or pharmacist immediately if you get any of these symptoms during and after the treatment with </strong><strong>Ondex.</strong></p><ul><li>if you experience sudden chest pain or chest tightness (myocardial ischemia).</li></ul><p><strong>Pregnancy and breast-feeding</strong><br />Only use during the first trimester of pregnancy after discussion with your doctor of the potential benefits and risks to you and your unborn baby of the different treatment options. This is because Ondex can slightly increase the risk of a baby being born with cleft lip and/or cleft palate (openings or splits in the upper lip and/or the roof of the mouth). If you are already pregnant, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking Ondex. If you are a woman of childbearing potential you may be advised to use effective contraception.</p><p>Do not breast-feed if you are taking Ondex. This is because small amounts pass into the mother&rsquo;s milk. Ask your doctor or midwife for advice.</p><p><strong>Important information about some of the ingredients of Ondex</strong><br />This medicine contains sorbitol. Calorific value 2.6 kcal/g sorbitol. If you have been told by your doctor that you have an intolerance to some sugars, speak to your doctor before taking this medicine. Sorbitol may have a mild laxative effect.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Ondex exactly as your doctor has told you. You should check with your doctor, nurse or pharmacist if you are not sure. The dose you have been prescribed will depend on the treatment you are having.</p><p>Do not mix Ondex with anything (not even water) before swallowing it.</p><p><strong>To prevent nausea and vomiting from chemotherapy or radiotherapy</strong><br />On the day of chemotherapy or radiotherapy</p><ul><li>the usual adult dose is 8 mg taken one to two hours before treatment and another 8 mg twelve hours after.</li></ul><p>On the following days</p><ul><li>the usual adult dose is two 5 ml spoonfuls twice a day</li><li>this may be given for up to 5 days.</li></ul><p>Children aged over 6 months and adolescents:<br />The doctor will decide the dose depending on the child&rsquo;s size (body surface area) or weight. Look at the label for more information.</p><ul><li>the usual dose for a child is up to one 5 ml spoonful twice a day</li><li>this can be given for up to 5 days.</li></ul><p><strong>To prevent nausea and vomiting after an operation</strong><br />The usual adult dose is four 5 ml spoonfuls before your operation.</p><p>Children aged over 1 month and adolescents:<br />It is recommended that Ondex is given as an injection.</p><p><strong>Patients with moderate or severe liver problems</strong><br />The total daily dose should not be more than 8 mg (two 5 ml spoonfuls).</p><p>Ondex should start to work within one or two hours of taking a dose.</p><p><strong>If you are sick (vomit) within one hour of taking a dose</strong></p><ul><li>take the same dose again</li><li>otherwise, do not take more Ondex than the label says.</li></ul><p>If you continue to feel sick, tell your doctor or nurse.</p><p><strong>If you take more Ondex than you should</strong><br />If you or your child take more Ondex than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you.</p><p><strong>If you forget to take Ondex</strong><br />If you miss a dose and feel sick or vomit:</p><ul><li>take Ondex as soon as possible, then</li><li>take your next dose at the usual time (as shown on the label)</li><li>do not take a double dose to make up for a forgotten dose.</li></ul><p>If you miss a dose but do not feel sick</p><ul><li>take the next dose as shown on the label</li><li>do not take a double dose to make up for a forgotten dose.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Some side effects could be serious</strong><br />Stop taking Ondex and seek medical help immediately if you or your child experience any of the following:<strong>&nbsp;</strong></p><p><strong>Allergic reactions</strong></p><ul><li>sudden wheezing and chest pain or chest tightness</li><li>swelling of your eyelids, face, lips, mouth or tongue</li><li>skin rash &ndash; red spots or lumps under your skin (hives) anywhere on your body</li><li>collapse.</li></ul><p>&nbsp;</p><p><strong>Myocardial ischemia</strong><br />Signs include:</p><ul><li>sudden chest pain or</li><li>chest tightness<strong>&nbsp;</strong></li></ul><p><strong>Other side effects include:<br />Very common (may affect more than 1 in 10 people)</strong></p><ul><li>headache.<strong>&nbsp;</strong></li></ul><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>a feeling of warmth or flushing</li><li>constipation</li><li>changes to liver function test results (if you take Ondex with a medicine called cisplatin, otherwise this side effect is uncommon)<strong>&nbsp;</strong></li></ul><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>hiccups</li><li>low blood pressure, which can make you feel faint or dizzy</li><li>uneven heart beat</li><li>chest pain</li><li>fits</li><li>unusual body movements or shaking.<strong>&nbsp;</strong></li></ul><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><ul><li>feeling dizzy or light headed</li><li>blurred vision</li><li>disturbance in heart rhythm (sometimes causing a sudden loss of consciousness)<strong>&nbsp;</strong></li></ul><p><strong>Very rare (may affect up to 1 in 10,000 people)</strong></p><ul><li>poor vision or temporary loss of eyesight, which usually comes back within 20 minutes.</li></ul><p><strong>Reporting of side effects</strong><br />If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use Ondex after the expiry date which is stated on the bottle after &lsquo;Exp&rsquo;. The expiry date refers to the last day of that month.<br />Store below 30&deg;C.<br />Do not refrigerate.<br />Use within 1 month after opening.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active ingredient is ondansetron. Each 5 ml spoonful of Ondex contains ondansetron 4 mg (as hydrochloride dihydrate).</li><li>The other ingredients are citric acid anhydrous, sodium benzoate, trisodium citrate dihydrate, sorbitol 70% solution, strawberry flavour and purified water.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ondex is a sugar-free, strawberry flavoured liquid. It is packed in glass bottles containing 50 ml of Ondex.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Pharmaceutical Industries<br />P.O. Box No.: 355127, Riyadh 11383<br />Kingdom of Saudi Arabia.<br />Tel: (+96611) 2650450, 2650354<br />Fax: (+96611) 2650383<br />Email: info@saudi-pharma.net</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي أونديكس على مادة دوائية تدعى أوندانسيترون. تنتمي إلى مجموعة دوائية تدعى مضادات القيء.</p><p dir="RTL">يستخدم أونديكس:</p><ul dir="rtl"><li>للوقاية من الغثيان والقيء الذي تسببه المعالجة الكيميائية (عند البالغين والأطفال) أو المعالجة الإشعاعية للسرطان (عند البالغين فقط)</li><li>للوقاية من الغثيان والقيء بعد الجراحة.</li></ul><p dir="RTL">اسأل طبيبك أو الممرض أو الصيدلي إذا كنت ترغب بمعرفة المزيد حول هذه الاستخدامات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أونديكس:</strong></p><ul dir="rtl"><li>إذا كنت تتناول آبومورفين (يستخدم لمعالجة داء باركنسون)</li><li>إذا كنت حساساً تجاه أوندانسيترون أو أي من المكونات الأخرى في أونديكس (المدرجة في القسم 6).</li></ul><p dir="RTL">إذا لم تكن متأكداً، تحدث إلى طبيبك أو الممرض أو الصيدلي قبل تناول أونديكس.</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><br />تأكد من طبيبك أو الممرض أو الصيدلي قبل تناول أونديكس:</p><ul dir="rtl"><li>إذا عانيت سابقاً من مشاكل في القلب (مثل فشل القلب الاحتقاني الذي يسبب ضيق النفس وتورم الكاحلين)</li><li>إذا كنت تعاني من عدم انتظام ضربات القلب (اضطرابات النظم)</li><li>إذا كنت حساساً تجاه أدوية مشابهة لأوندانسيترون، مثل غرانيسيترون أو بالونوسيترون</li><li>إذا كنت تعاني من مشاكل في الكبد</li><li>إذا كنت تعاني من انسداد (إحصار) في المعى</li><li>إذا كانت لديك مشاكل في مستويات الأملاح في دمك، مثل البوتاسيوم والصوديوم والمغنيزيوم.</li></ul><p dir="RTL">إذا لم تكن متأكداً إن كان أي مما سبق ينطبق على حالتك، فتحدث إلى طبيبك أو الممرض أو الصيدلي قبل تناول أونديكس.</p><p dir="RTL"><strong>الأدوية الأخرى وأونديكس</strong><br />أخبر طبيبك أو الممرض أو الصيدلي إذا كنت تتناول أو قد تناولت مؤخراً أو ربما تتناول أدوية أخرى. هذا يشمل الأدوية التي حصلت عليها دون وصفة طبية وكذلك الأدوية العشبية. وذلك لأن أونديكس يمكن أن يؤثر على آلية عمل بعض الأدوية. كذلك قد تؤثر بعض الأدوية الأخرى على آلية عمل أونديكس.</p><p dir="RTL">بشكل خاص، أخبر طبيبك أو الممرض أو الصيدلي إذا كنت تتناول أياً من الأدوية التالية:</p><ul dir="rtl"><li>كربامازيبين أو فنيتوين، يستخدمان لمعالجة الصرع</li><li>ريفامبيسين، يستخدم لمعالجة حالات العدوى مثل مرض السل</li><li>مضادات حيوية مثل إريثروميسين أو كيتوكونازول</li><li>أدوية مضادة لاضطراب النظم، تستخدم لمعالجة عدم انتظام ضربات القلب</li><li>الأدوية المحصرة للمستقبلات بيتا، تستخدم لمعالجة بعض المشاكل القلبية أو العينية، أو القلق أو الوقاية من حالات الشقيقة</li><li>ترامادول وهو مسكن للألم</li><li>الأدوية التي تؤثر على القلب (مثل هالوبيريدول أو ميثادون)</li><li>أدوية السرطان (بخاصة مجموعة الأنثراسيكلين وتراستوزوماب)</li><li>مثبطات إعادة امتصاص السيروتونين الانتقائية، تستخدم لمعالجة الاكتئاب و/أو القلق بما في ذلك فلوكستين وباروكستين وسرترالين وفلوفوكسامين وسيتالوبرام وإسيتالوبرام</li><li>مثبطات إعادة امتصاص السيروتونين والنورأدرينالين، تستخدم لمعالجة الاكتئاب و/أو القلق بما في ذلك فنلافاكسين ودولوكسيتين</li></ul><p dir="RTL">إذا لم تكن متأكداً إن كان أي مما سبق ينطبق على حالتك، فتحدث إلى طبيبك أو الممرض أو الصيدلي قبل تناول أونديكس.</p><p dir="RTL"><strong>إذا أصبت بأي من الأعراض التالية أثناء وبعد المعالجة بأونديكس، فأخبر طبيبك أو الصيدلي على الفور.</strong></p><ul dir="rtl"><li>إذا عانيت من ألم مفاجئ في الصدر أو ضيق في الصدر (نقص تروية عضلة القلب).</li></ul><p dir="RTL"><strong>&nbsp;الحمل والإرضاع</strong><br />يستخدم فقط خلال الأشهر الثلاثة الأولى من الحمل بعد التشاور مع طبيبك حول المنافع والمخاطر المحتملة لك وللجنين من خيارات العلاج المختلفة. وذلك لأن أونديكس يمكن أن يزيد قليلاً من خطر ولادة طفل مصاب بالشفة المشقوقة و/أو الحنك المشقوق (فتحات أو شقوق في الشفة العليا و/أو في سقف الفم). إذا كنت حاملاً بالفعل أو تعتقدين بأنك حامل أو تخططين للحمل فاستشيري طبيبك أو الصيدلي قبل تناول أونديكس. إذا كنت من النساء اللواتي يملكن القدرة على الإنجاب فربما يتم نصحك باستخدام مانع حمل فعال.</p><p dir="RTL">لا تقومي بالإرضاع الطبيعي إذا كنت تتناولين أونديكس. وذلك لأن كميات قليلة تنتقل إلى حليب الأم. اسألي طبيبك أو القابلة للحصول على المشورة.</p><p dir="RTL"><strong>معلومات مهمة عن بعض مكونات أونديكس</strong><br />يحتوي هذا الدواء على السوربيتول. القيمة الحرارية 2.6 كيلو كالوري/غ من السوربيتول. إذا أخبرك طبيبك بأن لديك عدم القدرة على تحمل بعض السكريات فتحدث إلى طبيبك قبل تناول هذا الدواء. قد يكون للسوربيتول تأثير ملين خفيف.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول أونديكس دائماً كما أخبرك طبيبك. يجب أن تراجع طبيبك أو الممرض أو الصيدلي إذا لم تكن متأكداً. تعتمد الجرعة التي توصف لك على المعالجة التي تتلقاها.</p><p dir="RTL">لا تقم بخلط أونديكس مع أي شيء آخر (ولا حتى مع الماء) قبل ابتلاعه.</p><p dir="RTL"><strong>للوقاية من الغثيان والقيء الناتج عن المعالجة الكيميائية أو المعالجة الإشعاعية</strong><br />في يوم المعالجة الكيميائية أو المعالجة الإشعاعية</p><ul dir="rtl"><li>الجرعة الاعتيادية للبالغين 8 ملغ يتم تناولها قبل ساعة أو ساعتين من المعالجة وجرعة أخرى 8 ملغ بعد 12 ساعة.</li></ul><p dir="RTL">في الأيام التالية</p><ul dir="rtl"><li>الجرعة الاعتيادية للبالغين ملعقتان 5 مل مرتان يومياً<br />يمكن أن تعطى هذه الجرعة لمدة تصل إلى 5 أيام.</li></ul><p dir="RTL">الأطفال بعمر أكبر من 6 شهور والمراهقون:<br />سيقرر الطبيب الجرعة اعتماداً على حجم الطفل (مساحة سطح الجسم) أو وزنه. راجع الملصق لمزيد من المعلومات.</p><ul dir="rtl"><li>الجرعة الاعتيادية للطفل تصل إلى ملعقة واحدة 5 مل مرتان يومياً</li><li>يمكن أن تعطى هذه الجرعة لمدة تصل إلى 5 أيام.</li></ul><p dir="RTL"><strong>للوقاية من الغثيان والقيء بعد إجراء عملية</strong><br />الجرعة الاعتيادية للبالغين هي 4 ملاعق 5 مل قبل العملية.</p><p dir="RTL">الأطفال بعمر أكبر من شهر والمراهقون:<br />يوصى بإعطاء أونديكس على شكل حقن.</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل متوسطة أو شديدة في الكبد</strong><br />يجب ألا يزيد إجمالي الجرعة اليومية عن 8 ملغ (ملعقتان 5 مل).<br />ينبغي أن يبدأ تأثير أونديكس خلال ساعة أو ساعتين من تناول الجرعة.</p><p dir="RTL"><strong>إذا شعرت بالغثيان (تقيأت) خلال ساعة من تناول الجرعة</strong></p><ul dir="rtl"><li>تناول الجرعة نفسها مجدداً</li><li>وبخلاف ذلك، لا تتناول من أونديكس أكثر مما هو مذكور على الملصق.</li></ul><p dir="RTL">إذا استمر شعورك بالغثيان فأخبر طبيبك أو الممرض.</p><p dir="RTL"><strong>إذا تناولت أونديكس أكثر مما ينبغي</strong><br />إذا تناولت أنت أو طفلك أكثر مما ينبغي من أونديكس فعليك التحدث إلى طبيب أو زيارة مستشفى على الفور. قم بأخذ عبوة الدواء معك.</p><p dir="RTL"><strong>إذا نسيت تناول أونديكس</strong><br />إذا نسيت تناول جرعة وشعرت بالغثيان أو القيء:</p><ul dir="rtl"><li>تناول أونديكس في أسرع وقت ممكن، ثم</li><li>تناول جرعتك التالية في الوقت المعتاد (كما هو موضح على الملصق)</li><li>لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة.</li></ul><p dir="RTL">إذا نسيت تناول جرعة ولكنك لم تشعر بالغثيان</p><ul dir="rtl"><li>تناول الجرعة التالية كما هو موضح على الملصق</li><li>لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب أعراضاً جانبية إلا أنها قد لا تحدث لدى كل الأشخاص.</p><p dir="RTL"><strong>قد تكون بعض الأعراض الجانبية خطيرة</strong><br />توقف عن تناول أونديكس واطلب المشورة الطبية على الفور إذا عانيت أنت أو طفلك من أي من الأعراض التالية:</p><p dir="RTL"><strong>التفاعلات التحسسية</strong></p><ul dir="rtl"><li>أزيز مفاجئ وألم في الصدر أو ضيق في الصدر</li><li>تورم في جفنيك أو وجهك أو شفتيك أو فمك أو لسانك</li><li>طفح جلدي &ndash; بقع حمراء أو كتل تحت جلدك (شرى) في أي مكان من جسمك</li><li>هبوط.</li></ul><p dir="RTL"><strong>نقص تروية عضلة القلب (إقفار عضلة القلب)</strong><br />تتضمن الأعراض:</p><ul dir="rtl"><li>ألماً مفاجئاً في الصدر أو</li><li>ضيقاً في الصدر</li></ul><p dir="RTL"><strong>&nbsp;تتضمن الأعراض الجانبية الأخرى:<br />شائعة جداً (قد تؤثر على أكثر من شخص من بين 10 أشخاص)</strong></p><ul dir="rtl"><li>صداع.</li></ul><p dir="RTL"><strong>شائعة (قد تؤثر على شخص من بين 10 أشخاص)</strong></p><ul dir="rtl"><li>شعور بالسخونة أو التوهج (احمرار الوجه)</li><li>إمساك</li><li>تغيرات في نتائج اختبارات وظيفة الكبد (إذا تناولت أونديكس مع دواء يدعى سيسبلاتين، وفيما عدا ذلك فإن هذا العرض الجانبي غير شائع)</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر على شخص من بين 100 شخص)</strong></p><ul dir="rtl"><li>فواق (حازوقة)</li><li>انخفاض ضغط الدم، الذي قد يجعلك تشعر بالإغماء أو الدوار</li><li>عدم انتظام ضربات القلب</li><li>ألم في الصدر</li><li>نوبات</li><li>حركات غير اعتيادية للجسم أو ارتعاش.</li></ul><p dir="RTL"><strong>نادرة (قد تؤثر على شخص من بين 1000 شخص)</strong></p><ul dir="rtl"><li>شعور بالدوار أو الدوخة</li><li>تغيم الرؤية</li><li>اضطراب في نظم القلب (يسبب أحياناً فقد الوعي بشكل مفاجئ)<strong>&nbsp;</strong></li></ul><p dir="RTL"><strong>نادرة جداً (قد تؤثر على شخص من بين 10000 شخص)</strong></p><ul dir="rtl"><li>ضعف في الرؤية أو فقد مؤقت للنظر، والذي عادة ما يعود خلال 20 دقيقة.</li></ul><p dir="RTL"><strong>&nbsp;الإبلاغ عن الأعراض الجانبية</strong><br />إذا أصبت بأية أعراض جانبية فتحدث إلى طبيبك أو الصيدلي أو الممرض. هذا يشمل أيضاً أية أعراض جانبية محتملة غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الأعراض الجانبية، فإنك تساعد على تقديم معلومات أكثر حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن متناول ومرأى الأطفال.<br />لا تستخدم أونديكس بعد تاريخ انتهاء الصلاحية الموضح على العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.<br />يخزن عند حرارة أقل من 30&deg;م.<br />لا يبرد.<br />يستخدم خلال شهر بعد فتح العبوة.<br />لا تقم بالتخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تحتاجها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul dir="rtl"><li>المادة الفعالة هي أوندانسيترون. تحتوي كل ملعقة 5 مل من أونديكس على 4 ملغ أوندانسيترون (على هيئة هيدروكلوريد ثنائي الهيدرات).</li><li>المكونات الأخرى هي حمض الستريك اللامائي، بنزوات الصوديوم، سيترات ثلاثية الصوديوم ثنائية الهدرات، محلول السوربيتول 70%، نكهة الفراولة، ماء منقى.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أونديكس عبارة عن سائل بطعم الفراولة خالٍ من السكر. يتوفر في عبوات زجاجية تحتوي على 50 مل من أونديكس.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">الشركة السعودية للصناعات الصيدلانية<br />صندوق بريد رقم: 355127، الرياض 11383<br />المملكة العربية السعودية.<br />هاتف: 2650354، 2650450 (96611+)<br />فاكس: 2650383 (96611+)<br />بريد إلكتروني: info@saudi-pharma.net</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ondex 4 mg/5 ml oral solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml contains 4 mg of ondansetron as the hydrochloride dihydrate.

Excipient(s) with known effect:
Each 5 ml also contain 2.31 g of sorbitol (see section 4.4).

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral solution.
Sugar-free strawberry flavoured liquid.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Adults:</u></em><br />Ondex is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.</p><p>Ondex is indicated for the prevention of post-operative nausea and vomiting (PONV).</p><p>For treatment of established PONV, administration by injection is recommended.</p><p><em><u>Paediatric Population:</u></em><br />Ondex is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged &ge; 6 months.</p><p>No studies have been conducted on the use of orally administered ondansetron in the prevention and treatment of PONV in children aged &ge; 1 month administration by IV injection is recommended for this purpose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology<br />Chemotherapy and radiotherapy induced nausea and vomiting (CINV and RINV)</u><br /><em>Adults</em><br />The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The selection of dose regimen should be determined by the severity of the emetogenic challenge.</p><p><em>Emetogenic chemotherapy and radiotherapy:</em> Ondex can be given either by oral, intravenous or intramuscular administration.</p><p>The recommended oral dose is 8 mg taken 1 to 2 hours before chemotherapy or radiation treatment, followed by 8 mg every 12 hours for a maximum of 5 days to protect against delayed or prolonged emesis.</p><p><em>For highly emetogenic chemotherapy:</em> a single dose of up to 24 mg Ondex taken with 12 mg oral dexamethasone sodium phosphate, 1 to 2 hours before chemotherapy, may be used.</p><p>To protect against delayed or prolonged emesis after the first 24 hours, oral treatment with Ondex may be continued for up to 5 days after a course of treatment.</p><p>The recommended dose for oral administration is 8 mg to be taken twice daily.</p><p><em>Paediatric Population<br />CINV in children and adolescents aged 6 months to 17 years</em><br />The dose for CINV can be calculated based on body surface area (BSA) or weight &ndash; see below. In paediatric clinical studies, ondansetron was given by IV infusion diluted in 25 to 50 ml of saline or other compatible infusion fluid and infused over not less than 15 minutes. &nbsp;<br />Weight-based dosing results in higher total daily doses compared to BSA-based dosing (see section 4.4).</p><p>There are no data from controlled clinical trials on the use of Ondex in the prevention of delayed or prolonged CINV. There are no data from controlled clinical trials on the use of Ondex for radiotherapy-induced nausea and vomiting in children.</p><p>Dosing by BSA<br />Ondex should be administered immediately before chemotherapy as a single intravenous dose of 5 mg/m<sup>2</sup>. The single intravenous dose must not exceed 8 mg.</p><p>Oral dosing can commence 12 hours later and may be continued for up to 5 days (Table 1). The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p><u>Table 1: BSA-based dosing for CINV (aged 6 months to 17 years)</u></p><table border="0" cellspacing="0" cellpadding="0" style="width:601px"><tbody><tr><td><p>BSA</p></td><td><p>Day 1 <sup>(a,b)</sup></p></td><td><p>Days 2 &ndash; 6 <sup>(b)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&lt; 0.6 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup> IV plus 2 mg oral solution after 12 hours</p></td><td style="vertical-align:top"><p>2 mg oral solution every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 0.6 m<sup>2</sup> to &le; 1.2 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup> IV plus 4 mg oral solution or tablet after 12 hours</p></td><td style="vertical-align:top"><p>4 mg oral solution every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1.2 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup> or 8 mg IV plus 8 mg oral solution after 12 hours</p></td><td style="vertical-align:top"><p>8 mg oral solution every 12 hours</p></td></tr></tbody></table><p>a The intravenous dose must not exceed 8 mg.<br />b The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>Dosing by bodyweight<br />Weight-based dosing results in higher total daily doses compared to BSA-based dosing (sections 4.4. and 5.1).<br />Ondex should be administered immediately before chemotherapy as a single intravenous dose of 0.15 mg/kg. The intravenous dose must not exceed 8 mg. Two further intravenous doses may be given in 4-hourly intervals.</p><p>Oral dosing can commence 12 hours later and may be continued for up to 5 days (Table 2).</p><p>The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p><u>Table 2: Weight-based dosing for CINV (aged 6 months to 17 years)</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:601px"><tbody><tr><td><p>Body Weight</p></td><td><p>Day 1 <sup>(a,b)</sup></p></td><td><p>Days 2-6 <sup>(b)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&le; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg IV every 4 hours</p></td><td style="vertical-align:top"><p>2 mg oral solution every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg IV every 4 hours</p></td><td style="vertical-align:top"><p>4 mg oral solution every 12 hours</p></td></tr></tbody></table><p>a The intravenous dose must not exceed 8 mg.</p><p>b The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p><em>Elderly</em><br />No alteration of oral dose or frequency of administration is required.</p><p><u>Post operative nausea and vomiting (PONV):</u><br /><em>Adults<br />For the prevention of PONV:</em> Ondex can be administered orally or by intravenous or intramuscular injection.</p><p>The recommended oral dose is 16 mg one hour prior to anaesthesia.</p><p>For the treatment of established PONV, intravenous or intramuscular administration is recommended.</p><p><em>Paediatric population<br />PONV in children and adolescents (aged 1 month to 17 years)<br />Oral formulation</em>:<br />No studies have been conducted on the use of orally administered ondansetron in the prevention or treatment of post-operative nausea and vomiting; slow IV injection (not less than 30 seconds) is recommended for this purpose.</p><p><em>Injection:</em><br />For prevention of PONV in paediatric patients having surgery performed under general anaesthesia, a single dose of ondansetron may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg either prior to, at or after induction of anaesthesia.</p><p>For the treatment of PONV after surgery in paediatric patients having surgery performed under general anaesthesia, a single dose of Ondex may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg.</p><p>There are no data on the use of Ondex in the treatment of PONV in children below 2 years of age.</p><p><em>Elderly</em><br />There is limited experience in the use of Ondex in the prevention and treatment of PONV in the elderly, however Ondex is well tolerated in patients over 65 years receiving chemotherapy.</p><p><u>For both indications:</u><br /><em>Patients with Renal impairment</em><br />No alteration of daily dosage or frequency of dosing, or route of administration are required.</p><p><em>Patients with Hepatic impairment</em><br />Clearance of Ondex is significantly reduced and serum half life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8 mg should not be exceeded.</p><p><em>Patients with poor Sparteine/Debrisoquine Metabolism</em><br />The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Concomitant use with apomorphine is contraindicated (see section 4.5 interactions).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT<sub>3</sub> receptor antagonists.</p><p>Respiratory events should be treated symptomatically and clinicians should pay particular attention to them as precursors of hypersensitivity reactions.</p><p>Ondansetron prolongs the QT interval in a dose-dependent manner (see section 5.1). In addition, post-marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.</p><p>Cases of myocardial ischemia have been reported in patients treated with ondansetron. In some patients, especially in the case of intravenous administration, symptoms appeared immediately after administration of ondansetron. Patients should be alerted to the signs and symptoms of myocardial ischemia.</p><p>There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRIs) (see section 4.5). If concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised.</p><p>As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.</p><p>In patients with adenotonsillar surgery prevention of nausea and vomiting with ondansetron may mask occult bleeding. Therefore, such patients should be followed carefully after ondansetron.</p><p>Patients with rare hereditary problems of fructose intolerance should not take this medicine as it contains sorbitol. Sorbitol may have a mild laxative effect and has a calorific value of 2.6 kcal/g.</p><p><em>Paediatric Population</em><br />Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function.</p><p><u>CINV</u>: When calculating the dose on an mg/kg basis and administering three doses at 4-hour intervals, the total daily dose will be higher than if one single dose of 5 mg/m<sup>2</sup> followed by an oral dose is given. The comparative efficacy of these two different dosing regimens has not been investigated in clinical trials. Cross-trial comparison indicates similar efficacy for both regimens (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly co-administered with it. Specific studies have shown that there are no interactions when ondansetron is administered with alcohol, temazepam, furosemide, alfentanil, tramadol, morphine, lidocaine, thiopental or propofol.</p><p>Ondansetron is metabolised by multiple hepatic cytochrome P-450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g., CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.</p><p>Caution should be exercised when ondansetron is coadministered with drugs that prolong the QT interval and/or cause electrolyte abnormalities. (See section 4.4).</p><p>Use of ondansetron with QT prolonging drugs may result in additional QT prolongation. Concomitant use of ondansetron with cardiotoxic drugs (e.g., anthracyclines (such as doxorubicin, daunorubicin) or trastuzumab), antibiotics (such as erythromycin), antifungals (such as ketoconazole), antiarrhythmics (such as amiodarone) and beta blockers (such as atenolol or timolol) may increase the risk of arrhythmias. (See section 4.4).</p><p><em>Serotonergic Drugs (e.g., SSRIs and SNRIs):</em> There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs). (See section 4.4).</p><p><em>Apomorphine:</em> Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.</p><p><em>Phenytoin, Carbamazepine and Rifampicin:</em> In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood concentrations were decreased.</p><p><em>Tramadol:</em> Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u><br />Women of childbearing potential should consider the use of contraception.</p><p><u>Pregnancy</u><br />Based on human experience from epidemiological studies, ondansetron is suspected to cause orofacial malformations when administered during the first trimester of pregnancy.</p><p>In one cohort study including 1.8 million pregnancies, first trimester ondansetron use was associated with an increased risk of oral clefts (3 additional cases per 10 000 women treated; adjusted relative risk, 1.24, (95% CI 1.03 &ndash; 1.48)).</p><p>The available epidemiological studies on cardiac malformations show conflicting results.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>Ondansetron should not be used during the first trimester of pregnancy.</p><p><u>Breast-feeding</u><br />Tests have shown that ondansetron passes into the milk of lactating animals. It is therefore recommended that mothers receiving Ondex should not breast-feed their babies.</p><p><u>Fertility</u><br />There is no information on the effects of ondansetron on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ondex has no or negligible influence on the ability to drive and use machines.</p><p>In psychomotor testing ondansetron does not impair performance nor cause sedation.</p><p>No detrimental effects on such activities are predicted from the pharmacology of ondansetron.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tabulated list of adverse reactions</u><br />Adverse events are listed below by system organ class and frequency. Frequencies are defined as:<br />very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge; 1/1000 to &lt; 1/100), rare (&ge; 1/10,000 to &lt; 1/1000) and very rare (&lt; 1/10,000). Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo was taken into account. Rare, very rare and not known events were generally determined from post-marketing spontaneous data.</p><p>The following frequencies are estimated at the standard recommended doses of ondansetron. The adverse event profiles in children and adolescents were comparable to that seen in adults.</p><table border="1" cellspacing="0" cellpadding="0" style="width:601px"><tbody><tr><td colspan="2"><p><strong>Immune system disorders</strong></p></td></tr><tr><td><p>Rare:</p></td><td><p>Immediate hypersensitivity reactions sometimes severe, including anaphylaxis.</p></td></tr><tr><td colspan="2"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td><p>Very common:</p></td><td><p>Headache.</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Seizures, movement disorders (including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia) <sup>(1)</sup>.</p></td></tr><tr><td><p>Rare:</p></td><td><p>Dizziness predominantly during rapid IV administration.</p></td></tr><tr><td colspan="2"><p><strong>Eye disorders</strong></p></td></tr><tr><td><p>Rare:</p></td><td><p>Transient visual disturbances (e.g., blurred vision) predominantly during IV administration.</p></td></tr><tr><td><p>Very rare:</p></td><td><p>Transient blindness predominantly during IV administration <sup>(2)</sup>.</p></td></tr><tr><td colspan="2"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Arrhythmias, chest pain with or without ST segment depression, bradycardia.</p></td></tr><tr><td><p>Rare:</p></td><td><p>QTc prolongation (including Torsade de Pointes).</p></td></tr><tr><td><p>Not known</p></td><td><p>Myocardial ischemia* (see section 4.4)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:601px"><tbody><tr><td colspan="3"><p><strong>Vascular disorders</strong></p></td></tr><tr><td><p>Common:</p></td><td colspan="2"><p>Sensation of warmth or flushing.</p></td></tr><tr><td><p>Uncommon:</p></td><td colspan="2"><p>Hypotension.</p></td></tr><tr><td colspan="3"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p>Uncommon:</p></td><td colspan="2"><p>Hiccups.</p></td></tr><tr><td colspan="3"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td colspan="2"><p>Common:</p></td><td><p>Constipation.</p></td></tr><tr><td colspan="3"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td colspan="2"><p>Uncommon:</p></td><td><p>Asymptomatic increases in liver function tests <sup>(3)</sup>.</p></td></tr><tr><td colspan="3"><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Observed without definitive evidence of persistent clinical sequelae.<br />2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The majority of the blindness cases reported resolved within 20 minutes. Most patients had received chemotherapeutic agents, which included cisplatin. Some cases of transient blindness were reported as cortical in origin.<br />3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These events were observed commonly in patients receiving chemotherapy with cisplatin.<br />* These types of adverse drug reactions have been derived from post-marketing experience with Ondex via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known.</p></td></tr></tbody></table><p><u>Reporting of suspected adverse reactions</u><br />Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><u>To reports any side effect(s):</u></p><ul><li><strong><em>Saudi Arabia:</em></strong></li></ul><p>The National Pharmacovigilance Centre (NPC):</p><ul><li>SFDA Call Center: 19999</li><li>Email: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul><ul><li><strong><em>Other GCC States:</em></strong></li></ul><p>​​​​​​​Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and Signs</u><br />There is limited experience of ondansetron overdose. In the majority of cases, symptoms were similar to those already reported in patients receiving recommended doses (see section 4.8). Manifestations that have been reported include visual disturbances, severe constipation, hypotension and a vasovagal episode with transient second-degree AV block.</p><p>Ondansetron prolongs the QT interval in a dose-dependent fashion. ECG monitoring is recommended in cases of overdose.</p><p><em><u>Paediatric population</u></em><br />Paediatric cases consistent with serotonin syndrome have been reported after inadvertent oral overdoses of ondansetron (exceeded estimated ingestion of 4 mg/kg) in infants and children aged 12 months to 2 years.</p><p><u>Management</u><br />There is no specific antidote for ondansetron, therefore in all cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate.</p><p>Further management should be as clinically indicated or as recommended by the national poisons center, where available.</p><p>The use of ipecacuanha to treat overdose with ondansetron is not recommended, as patients are unlikely to respond due to the anti-emetic action of ondansetron itself.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiemetics and antinauseants, Serotonin (5HT<sub>3</sub>) antagonists ATC Code: A04AA01</p><p><u>Mechanism of Action</u><br />Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system.</p><p>The mechanisms of action in post operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.</p><p>Ondansetron does not alter plasma prolactin concentrations.</p><p><u>Clinical safety and efficacy</u><br />The role of ondansetron in opiate-induced emesis is not yet established.</p><p><u>QT Prolongation</u><br />The effect of ondansetron on the QTc interval was evaluated in a double blind, randomised, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women. Ondansetron doses included 8 mg and 32 mg infused intravenously over 15 minutes. At the highest tested dose of 32 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 19.6 (21.5) msec. At the lower tested dose of 8 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 5.8 (7.8) msec. In this study, there were no QTcF measurements greater than 480 msec and no QTcF prolongation was greater than 60 msec.</p><p><em><u>Paediatric population</u></em><br /><u>CINV</u><br />The efficacy of ondansetron in the control of emesis and nausea induced by cancer chemotherapy was assessed in a double-blind randomised trial in 415 patients aged 1 to 18 years (S3AB3006). On the days of chemotherapy, patients received either ondansetron 5 mg/m<sup>2</sup> intravenous and ondansetron 4 mg orally after 8 to 12 hours or ondansetron 0.45 mg/kg intravenous and placebo orally after 8 to 12 hours. Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. Complete control of emesis on worst day of chemotherapy was 49% (5 mg/m<sup>2</sup> intravenous and ondansetron 4 mg orally) and 41% (0.45 mg/kg intravenous and placebo orally). Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>A double-blind randomised placebo-controlled trial (S3AB4003) in 438 patients aged 1 to 17 years demonstrated complete control of emesis on worst day of chemotherapy in:</p><ul><li>73% of patients when ondansetron was administered intravenously at a dose of 5 mg/m<sup>2</sup> intravenous together with 2 to 4 mg dexamethasone orally</li><li>71% of patients when ondansetron was administered as syrup at a dose of 8 mg together with 2 to 4 mg dexamethasone orally on the days of chemotherapy.</li></ul><p>Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 2 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>The efficacy of ondansetron in 75 children aged 6 to 48 months was investigated in an open-label, non-comparative, single-arm study (S3A40320). All children received three 0.15 mg/kg doses of intravenous ondansetron, administered 30 minutes before the start of chemotherapy and then at 4 and 8 hours after the first dose. Complete control of emesis was achieved in 56% of patients.</p><p>Another open-label, non-comparative, single-arm study (S3A239) investigated the efficacy of one intravenous dose of 0.15 mg/kg ondansetron followed by two oral ondansetron doses of 4 mg for children aged &lt; 12 years and 8 mg for children aged &ge; 12 years (total no. of children n = 28). Complete control of emesis was achieved in 42% of patients.</p><p><u>PONV</u><br />The efficacy of a single dose of ondansetron in the prevention of post-operative nausea and vomiting was investigated in a randomised, double-blind, placebo-controlled study in 670 children aged 1 to 24 months (post-conceptual age &ge; 44 weeks, weight &ge; 3 kg). Included subjects were scheduled to undergo elective surgery under general anaesthesia and had an ASA status &le; III. A single dose of ondansetron 0.1 mg/kg was administered within five minutes following induction of anaesthesia. The proportion of subjects who experienced at least one emetic episode during the 24-hour assessment period (ITT) was greater for patients on placebo than those receiving ondansetron (28% vs. 11%, p &lt; 0.0001).</p><p>Four double-blind, placebo-controlled studies have been performed in 1469 male and female patients (2 to 12 years of age) undergoing general anaesthesia. Patients were randomised to either single intravenous doses of ondansetron (0.1 mg/kg for paediatric patients weighing 40 kg or less, 4 mg for paediatric patients weighing more than 40 kg; number of patients = 735) or placebo (number of patients = 734). Study drug was administered over at least 30 seconds, immediately prior to or following anaesthesia induction. Ondansetron was significantly more effective than placebo in preventing nausea and vomiting. The results of these studies are summarised in Table 3.</p><p><u>Table 3: Prevention and treatment of PONV in Paediatric Patients &ndash; Treatment response over 24 hours</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Study</p></td><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p>Ondansetron %</p></td><td style="vertical-align:top"><p>Placebo %</p></td><td style="vertical-align:top"><p>p value</p></td></tr><tr><td style="vertical-align:top"><p>S3A380</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>&le; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT09</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>&le; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3A381</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&le; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no nausea</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no emesis</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>0.004</p></td></tr></tbody></table><p>CR = no emetic episodes, rescue or withdrawal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u><br />Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism. Peak plasma concentrations of about 30 ng/ml are attained approximately 1.5 hours after an 8 mg dose. For doses above 8 mg the increase in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first pass metabolism at higher oral doses. Mean bioavailability in healthy male subjects, following the oral administration of a single 8 mg tablet, is approximately 55 to 60%. Bioavailability, following oral administration, is slightly enhanced by the presence of food but unaffected by antacids. The disposition of ondansetron following oral, intramuscular (IM) and intravenous (IV) dosing is similar with a terminal half life of about 3 hours and steady state volume of distribution of about 140 l. Equivalent systemic exposure is achieved after IM and IV administration of ondansetron.</p><p>A 4 mg intravenous infusion of ondansetron given over 5 minutes results in peak plasma concentrations of about 65 ng/ml. Following intramuscular administration of ondansetron, peak plasma concentrations of about 25 ng/ml are attained within 10 minutes of injection.</p><p>Following administration of ondansetron suppository, plasma ondansetron concentrations become detectable between 15 and 60 minutes after dosing. Concentrations rise in an essentially linear fashion, until peak concentrations of 20 &ndash; 30 ng/ml are attained, typically 6 hours after dosing. Plasma concentrations then fall, but at a slower rate than observed following oral dosing due to continued absorption of ondansetron. The absolute bioavailability of ondansetron from the suppository is approximately 60% and is not affected by gender. The half life of the elimination phase following suppository administration is determined by the rate of ondansetron absorption, not systemic clearance and is approximately 6 hours. Females show a small, clinically insignificant, increase in half-life in comparison with males.</p><p><u>Distribution</u><br />Ondansetron is not highly protein bound (70 &ndash; 76%).</p><p><u>Biotransformation and Elimination</u><br />Ondansetron is cleared from the systemic circulation predominantly by hepatic metabolism through multiple enzymatic pathways. Less than 5% of the absorbed dose is excreted unchanged in the urine. The absence of the enzyme CYP2D6 (the debrisoquine polymorphism) has no effect on ondansetron&#39;s pharmacokinetics. The pharmacokinetic properties of ondansetron are unchanged on repeat dosing.</p><p><u>Special Patient Populations</u><br /><em>Gender</em><br />Gender differences were shown in the disposition of ondansetron, with females having a greater rate and extent of absorption following an oral dose and reduced systemic clearance and volume of distribution (adjusted for weight).</p><p><em>Children and Adolescents (aged 1 month to 17 years)</em><br />In paediatric patients aged 1 to 4 months (n=19) undergoing surgery, weight normalised clearance was approximately 30% slower than in patients aged 5 to 24 months (n=22) but comparable to the patients aged 3 to 12 years. The half-life in the patient population aged 1 to 4 month was reported to average 6.7 hours compared to 2.9 hours for patients in the 5 to 24 month and 3 to 12 year age range. The differences in pharmacokinetic parameters in the 1 to 4 month patient population can be explained in part by the higher percentage of total body water in neonates and infants and a higher volume of distribution for water soluble drugs like ondansetron.</p><p>In paediatric patients aged 3 to 12 years undergoing elective surgery with general anaesthesia, the absolute values for both the clearance and volume of distribution of ondansetron were reduced in comparison to values with adult patients. Both parameters increased in a linear fashion with weight and by 12 years of age, the values were approaching those of young adults. When clearance and volume of distribution values were normalised by body weight, the values for these parameters were similar between the different age group populations. Use of weight-based dosing compensates for age-related changes and is effective in normalising systemic exposure in paediatric patients.</p><p>Population pharmacokinetic analysis was performed on 428 subjects (cancer patients, surgery patients and healthy volunteers) aged 1 month to 44 years following intravenous administration of ondansetron. Based on this analysis, systemic exposure (AUC) of ondansetron following oral or IV dosing in children and adolescents was comparable to adults, with the exception of infants aged 1 to 4 months. Volume was related to age and was lower in adults than in infants and children. Clearance was related to weight but not to age with the exception of infants aged 1 to 4 months. It is difficult to conclude whether there was an additional reduction in clearance related to age in infants 1 to 4 months or simply inherent variability due to the low number of subjects studied in this age group. Since patients less than 6 months of age will only receive a single dose in PONV a decreased clearance is not likely to be clinically relevant.</p><p><em>Elderly</em><br />Early Phase I studies in healthy elderly volunteers showed a slight age-related decrease in clearance, and an increase in half-life of ondansetron. However, wide inter-subject variability resulted in considerable overlap in pharmacokinetic parameters between young (&lt; 65 years of age) and elderly subjects (&ge; 65 years of age) and there were no overall differences in safety or efficacy observed between young and elderly cancer patients enrolled in CINV clinical trials to support a different dosing recommendation for the elderly.</p><p>Based on more recent ondansetron plasma concentrations and exposure-response modelling, a greater effect on QTcF is predicted in patients &ge; 75 years of age compared to young adults. Specific dosing information is provided for patients over 65 years of age and over 75 years of age for intravenous dosing.</p><p><em>Renal impairment</em><br />In patients with renal impairment (creatinine clearance 15 &ndash; 60 ml/min), both systemic clearance and volume of distribution are reduced following IV administration of ondansetron, resulting in a slight, but clinically insignificant, increase in elimination half-life (5.4 hours). A study in patients with severe renal impairment who required regular haemodialysis (studied between dialyses) showed ondansetron&#39;s pharmacokinetics to be essentially unchanged following IV administration.</p><p><em>Hepatic impairment</em><br />Following oral, intravenous or intramuscular dosing in patients with severe hepatic impairment, ondansetron&#39;s systemic clearance is markedly reduced with prolonged elimination half-lives (15 &ndash; 32 hours) and an oral bioavailability approaching 100% due to reduced pre-systemic metabolism. The pharmacokinetics of ondansetron following administration as a suppository have not been evaluated in patients with hepatic impairment. The pharmacokinetics of ondansetron following administration as a suppository have not been evaluated in patients with hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Embryo-fetal development studies in rats and rabbits did not show evidence of harm to the fetus when ondansetron was administered during the period of organogenesis at approximately 6 and 24 times respectively the maximum recommended human oral dose of 24 mg/day, based on body surface area. In a pre- and postnatal developmental toxicity study, there were no effects upon pregnant rats and the pre- and postnatal development of their offspring, including reproductive performance at approximately 6 times the maximum recommended human oral dose of 24 mg/day based on body surface area.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citrate acid anhydrous<br />Sodium benzoate<br />Trisodium citrate dihydrate<br />Sorbitol 70% solution<br />Strawberry flavour<br />Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
After first opening: 1 month.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.<br />Do not refrigerate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>60 ml amber glass bottle with a child resistant cap containing 50 ml of Ondex oral solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.<br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Pharmaceutical Industries
P.O. Box No.: 355127, Riyadh 11383
Kingdom of Saudi Arabia.
Tel: (+96611) 2650450, 2650354
Fax: (+96611) 2650383
Email: info@saudi-pharma.net
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>